The AGAP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. This product provides a loss-of-function model with targeted disruption of the AGAP1 gene, which encodes an Arf GTPase-activating protein. The polyclonal format ensures a diverse genetic background, enabling robust assessment of AGAP1-dependent phenotypes. By ablating AGAP1 expression, researchers can interrogate its role in endosomal trafficking and actin cytoskeleton dynamics within a physiologically relevant intestinal epithelial context.
HT29 cells are a well-characterized colorectal adenocarcinoma line originally isolated from a 44-year-old Caucasian female. These epithelial cells exhibit differentiation capability under appropriate culture conditions, making them a valuable model for intestinal biology and colorectal cancer research. Their capacity to form polarized monolayers and to undergo enterocytic differentiation supports studies of epithelial barrier function, signal transduction, and tumor progression. Importantly, HT29 cells retain functional EGFR signaling pathways, which are directly linked to AGAP1-mediated endocytic trafficking.
AGAP1 functions as a GTPase-activating protein for Arf6, accelerating GTP hydrolysis to regulate Arf6 cycling between active and inactive states. This activity controls endosomal membrane trafficking and actin polymerization. Upstream, AGAP1 is regulated by EGFR activation, PI3K signaling, and phosphoinositide binding. Downstream, it influences Arf6, Rac1, PAK, and actin filament assembly. AGAP1 interacts with the AP-2 complex, clathrin, and EGFR itself, positioning it at the nexus of EGFR endocytosis and actin remodeling. The mechanistic interplay places AGAP1 within the Arf6?CRac1?Cactin signaling axis, coordinating receptor internalization with cytoskeletal rearrangements.
In the HT29 colorectal cancer background, AGAP1 depletion can disrupt EGFR endocytosis, potentially altering downstream signaling cascades that govern cell proliferation, migration, and survival. This model is particularly relevant for dissecting how aberrant endosomal trafficking contributes to tumor progression and metastatic behavior. Given the role of Arf6 in cancer cell invasion and adhesion, the knockout cells provide a tractable system to investigate AGAP1??s involvement in colorectal cancer pathogenesis. The epithelial nature of HT29 cells further allows examination of polarity and junctional dynamics following loss of AGAP1 function.
Representative applications include Western blotting for AGAP1 and Arf6, immunofluorescence staining of actin and endosomal markers, EGFR internalization assays, cell proliferation and migration studies, co-immunoprecipitation for interaction partners such as clathrin or AP-2, and RT-qPCR analysis of downstream target genes. These assays enable functional dissection of AGAP1-dependent pathways and evaluation of chemotherapeutic responses in a colorectal cancer model. The polyclonal knockout population is suitable for both endpoint and kinetic assays, supporting drug screening and mechanistic investigations. For additional information or technical support, please contact Ascent Research.
